Medical Experts
Karner
Ng
Minimal residual disease (MRD, also referred to as measurable residual disease) describes the small numbers of malignant cells that may persist after treatment and remain below the threshold of detection for conventional disease assessment. MRD is a strong predictor of relapse in many hematologic malignancies and has important implications for prognosis and treatment decision-making. MRD assessment is most established in hematologic malignancies, including leukemias and multiple myeloma, although MRD approaches are increasingly being investigated in solid tumors. Highly sensitive laboratory techniques can detect very small numbers of residual malignant cells and enable MRD assessment in clinical practice. Laboratory methods used for MRD assessment include polymerase chain reaction (PCR), massively parallel sequencing (MPS, also known as next generation sequencing [NGS]), and multiparameter flow cytometry.
Quick Answers for Clinicians
The National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and the European Hematology Association (EHA) recommend minimal residual disease (MRD) assessment for specific hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL, including pediatric ALL), chronic myeloid leukemia (CML), and multiple myeloma. - MRD may also be assessed in some other hematologic malignancies. In chronic lymphocytic leukemia (CLL), the NCCN supports MRD assessment in routine practice to guide treatment duration. In mantle cell lymphoma, MRD is incorporated into response-based treatment decision-making. In myeloid/lymphoid neoplasms with eosinophilia, next generation sequencing-based MRD monitoring is an emerging adjunct for diagnosis and monitoring.
The role of minimal residual disease (MRD) assessment in patients with solid tumors (e.g., melanoma, lung cancer, and breast cancer) is currently being researched. Circulating tumor DNA (ctDNA)-based MRD assessment has supportive evidence for prognostic value, but its clinical utility for directing therapy is unclear. MRD testing is therefore not currently recommended to guide treatment in solid tumors.
Indications for Testing
MRD testing may be used in hematologic malignancies to:
- Assess treatment response and inform treatment decisions
- Determine prognosis
- Monitor remission and detect recurrence
Laboratory Testing
Testing Methods
MRD assessment is used across multiple hematologic malignancies, including acute lymphoblastic leukemia (ALL, including pediatric ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), lymphomas, and multiple myeloma. Recommended methodologies, specimen requirements, and clinical applications vary by disease. Clinicians should select MRD testing approaches that are supported by disease-specific guidelines and validated for the malignancy being assessed.
In multiple myeloma, the two most widely accepted methods for MRD assessment are next generation flow cytometry (NGF) and MPS. Both methodologies are incorporated into contemporary response criteria and clinical practice guidelines. For example, the International Myeloma Working Group (IMWG) recognizes both approaches as meeting requirements for high-sensitivity MRD detection, with sensitivity of at least 10-5. The National Comprehensive Cancer Network (NCCN) has subsequently incorporated both methodologies into its guidance on MRD assessment.
Although NGF and NGS use different technologies, they demonstrate high concordance and similar prognostic performance when performed on the same specimen. Consequently, selection between methodologies is often driven less by differences in clinical validity than by practical considerations, including specimen requirements, laboratory availability, turnaround time, and disease-specific recommendations.
NGF refers to highly standardized flow cytometric approaches for MRD detection that use expanded antibody panels, acquisition of large numbers of cellular events, and standardized analytic methods to improve sensitivity as compared with traditional flow cytometry. Spectral flow technology further expands these capabilities by measuring the full emission profile of each fluorochrome and applying computational unmixing algorithms to resolve overlapping signals. This methodology enables high-parameter MRD assays to incorporate expanded marker panels within a single tube.
The following table summarizes practical considerations that may influence selection of NGF- or NGS-based MRD testing in multiple myeloma.
Clinicians should consult disease-specific guidelines and laboratory test information when selecting an MRD assay, as preferred methodologies, specimen requirements, and reporting practices may differ among hematologic malignancies.
MRD Assessment in Specific Hematologic Malignancies
For more information about MRD testing and other laboratory testing in specific hematologic malignancies, refer to the following ARUP Consult topics:
- Acute Lymphoblastic Leukemia - ALL (covers B-cell ALL, or B-ALL)
- Acute Myeloid Leukemia - AML
- Chronic Lymphocytic Leukemia - CLL
- Chronic Myeloid Leukemia - CML
- Plasma Cell Dyscrasias (covers multiple myeloma)
ARUP Laboratory Tests
Quantitative Reverse Transcription Polymerase Chain Reaction
Quantitative Reverse Transcription Polymerase Chain Reaction
Quantitative Reverse Transcription Polymerase Chain Reaction
Reverse Transcription Polymerase Chain Reaction
Quantitative Reverse Transcription Polymerase Chain Reaction
Flow Cytometry
Reverse Transcription Polymerase Chain Reaction
Flow Cytometry
Flow Cytometry
References
-
NCCN - Acute lymphoblastic leukemia v3.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: acute lymphoblastic leukemia. Version 3.2026. Updated Sep 2026; accessed Sep 2026.
-
27056999
Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69-v82.
-
NCCN - acute myeloid leukemia, v5.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: acute myeloid leukemia. Version 5.2026. Updated Jul 2026; accessed Sep 2026.
-
32171751
Heuser M, Ofran Y, Boissel N, et, al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697-712.
-
NCCN - Chronic myeloid leukemia v2.2027
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: chronic myeloid leukemia. Version 2.2027. Updated Jul 2026; accessed Sep 2026.
-
NCCN - Multiple myeloma v2.2027
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: multiple myeloma. Version 2.2027. Updated Sep 2026; accessed Oct 2026.
-
40624367
Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680-700.
-
NCCN - pediatric acute lymphoblastic leukemia v1.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: pediatric acute lymphoblastic leukemia. Version 1.2026. Updated Aug 2025; accessed Sep 2026.
-
NCCN - chronic lymphocytic leukemia-small lymphocytic lymphoma v1.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 1.2026. Updated Oct 2025; accessed Oct 2025.
-
NCCN - B-cell lymphomas v4.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. Version 4.2026. Updated May 2026; accessed Sep 2026.
-
NCCN - myeloid-lymphoid neoplasms with eosinophilia v1.2026
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes. Version 1.2026. Updated Oct 2025; accessed Oct 2025.
-
42314080
Lockwood CM, Messersmith HJ, Kim AS, et al. Circulating tumor DNA testing in solid tumors and lymphoma: ASCO guideline. JCO Oncol Pract. 2026;22(9):1468-1489.
-
27511158
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346.
-
40195455
Paiva B, Shi Q, Puig N, et al. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025;22(6):424-438.
-
39451039
Vardaman D 3rd, Ali MA, Siam MHB, et al. Development of a spectral flow cytometry analysis pipeline for high-dimensional immune cell characterization. J Immunol. 2024;213(11):1713-1724.
-
41350429
Zanwar S, Rajkumar SV. Measurable residual disease assessment in multiple myeloma. Leukemia. 2026;40(1):25-28.
-
32778736
Costa LJ, Derman BA, Bal S, e al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18-30.
-
37235573
Marx A, Osváth M, Szikora B, et al. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes-A feasibility study. PLoS One. 2023;18(5):e0285696.


Cite this page